We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




RBC Transporters Used for Targeting Nanoparticle Drug Carriers

By LabMedica International staff writers
Posted on 14 Aug 2018
Print article
Image: Red blood cells can safely transport nanoscale drug carriers to chosen organs by targeted placement of intravascular catheters (Photo courtesy of the University of Pennsylvania).
Image: Red blood cells can safely transport nanoscale drug carriers to chosen organs by targeted placement of intravascular catheters (Photo courtesy of the University of Pennsylvania).
A novel, patent pending nanoparticle drug delivery system uses red blood cells to transport drug carriers directly to selected target organs with minimal exposure to other areas of the body.

The used of nanocarriers (NCs) for drug delivery has been complicated by the dominant uptake of the particles by the liver and subsequent limited target organ deposition, even when the NCs were targeted using affinity markers.

To increase the precision of NC drug transport, investigators at the University of Pennsylvania (Philadelphia, USA) devised a universal solution: red blood cell (RBC)-hitchhiking (RH), in which NCs adsorbed onto the RBCs transferred from RBCs to the first organ downstream of the intravascular injection. This approach significantly increased the concentration of drugs ferried to selected organs.

The investigators reported the outcome of a proof-of-principle study in the July 11, 2018, online edition of the journal Nature Communications. They said in this paper that use of RH carriers increased drug uptake in the lungs by about 40-fold following intravenous injection as compared to absorption of freely circulating drug carriers. Furthermore, injection of RH drug carriers into the carotid artery delivered about 10% of the injected dose to the brain, an amount that was approximately 10 times higher than what was obtained by using antibodies to guide drug carriers to target organs. The investigators further reported that RH worked in mice, pigs, and ex vivo human lungs without causing RBC or end-organ toxicities.

“Red blood cells are a particularly attractive carrier due to their biocompatibility and known safety in transfusions,” said senior author Dr. Vladimir Muzykantov, professor of systems pharmacology and translational therapeutics at the University of Pennsylvania. “In just a few short years since we began this work, we are now on the brink of mapping out ways to test it in clinical trials. The body’s largest surface area of cell-to-cell interaction is observed between red blood cells and blood vessel linings, so it is intriguing to think that our RH technology has uncovered a phenomenon in which RBCs naturally transport cargo on their surfaces.”

Related Links:
University of Pennsylvania

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.